Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM
Original Article from The New England Journal of Medicine — Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Original Article from The New England Journal of Medicine — Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Governments recently adopted new global targets to halt and reverse the loss of biodiversity. It is therefore crucial to understand the outcomes of conservation actions.…
Orthopaedic surgeon and activist Simon Fleming explains why he has spent years trying to change the culture in health care to a safe and respectful…
Dr. J. Donald Temple, a renowned hematologist and longtime member of the Miller School of Medicine family, passed away on April 26.
Esophageal squamous cell carcinoma (ESCC) is a leading cause of death worldwide, particularly prevalent in Southern and Eastern Africa, and central Asia. Initia…
Esophageal squamous cell carcinoma (ESCC) is a leading cause of death worldwide, particularly prevalent in Southern and Eastern Africa, and central Asia. Initia…
Esophageal cancer is amongst the most common types of cancer in Asia. It is a deadly disease where incidence almost parallels mortality. It is of…
KEY POINTS In 2022, The College of Family Physicians of Canada (CFPC) published its final report of the Outcomes of Training Project, including the recommendation…
Perspective from The New England Journal of Medicine — The New USPSTF Mammography Recommendations — A Dissenting View
Advances in Therapy – According to current guidelines, targeted therapy with a combination of BRAF plus MEK inhibitors is the preferred first-line treatment for patients…
The world’s most influential people in health have made fresh discoveries, dreamed up novel treatments, and pioneered global victories over disease.